| Brianna Elaine Dunn, | |
|
1345 Birch Ave, Cottage Grove, OR 97424-1416 | |
| (541) 942-3939 | |
| Not Available |
| Full Name | Brianna Elaine Dunn |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 1345 Birch Ave, Cottage Grove, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003579285 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brianna Elaine Dunn, 1345 Birch Ave, Cottage Grove, OR 97424-1416 Ph: (541) 767-6095 | Brianna Elaine Dunn, 1345 Birch Ave, Cottage Grove, OR 97424-1416 Ph: (541) 942-3939 |
News Archive
Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.
For decades, neuroscientists and physicians have tried to get to the bottom of the age-old mystery of post-traumatic stress disorder, to explain why only some people are vulnerable and why they experience so many symptoms and so much disability.
Targeting children may be an effective use of limited supplies of flu vaccine, according to research funded by the Wellcome Trust and the EU. The study suggests that, used to support other control measures, this could help control the spread of pandemics such as the current swine flu.
Benitec Biopharma Limited, a clinical-stage biotechnology company developing innovative therapeutics based on its gene-silencing technology, DNA-directed RNA interference (ddRNAi), is pleased to announce it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas.
The Norwegian pharmaceutical company Lytix Biopharma AS today announced approvals from the Norwegian Medicines Agency ("Statens legemiddelverk") and the Swedish Medical Products Agency ("Läkemedelverket") to commence Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.
› Verified 5 days ago
Therese N Mastin, M.A., QMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 1345 Birch Ave, Cottage Grove, OR 97424 Phone: 541-942-3939 Fax: 541-942-9310 | |
Sonja Therese Towner, Counselor Medicare: Not Enrolled in Medicare Practice Location: 37 N 6th St, Cottage Grove, OR 97424 Phone: 541-942-3939 | |
Tessa Hart, MED, QMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 1345 Birch Ave, Cottage Grove, OR 97424 Phone: 541-942-3939 | |
Susan Grzesiak, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1345 Birch Ave, Cottage Grove, OR 97424 Phone: 541-942-3939 Fax: 541-942-9310 | |
Robert H Lee, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1345 Birch Ave, Cottage Grove, OR 97424 Phone: 541-942-3939 Fax: 541-942-9310 | |
Mrs. Sarah Marie Baker, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1245 Birch Ave, Cottage Grove, OR 97424 Phone: 541-942-3939 |